Vildagliptin ameliorates biochemical, metabolic and fatty changes associated with non alcoholic fatty liver disease

OBJECTIVE: To determine the effect of Vildagliptin in non-alcoholic, fatty liver disease patients with dyslipidemia. METHODS: A randomized placebo controlled trial was conducted at outpatient clinic of Medical Unit-I of Sheikh Zayed Medical College/Hospital, Rahim Yar Khan, in which fifty eight pati...

Descripción completa

Detalles Bibliográficos
Autores principales: Hussain, Mazhar, Majeed Babar, Muhammad Zafar, Hussain, Muhammad Shahbaz, Akhtar, Lubna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Professional Medical Publications 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216289/
https://www.ncbi.nlm.nih.gov/pubmed/28083033
http://dx.doi.org/10.12669/pjms.326.11133

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5216289/
https://www.ncbi.nlm.nih.gov/pubmed/28083033
http://dx.doi.org/10.12669/pjms.326.11133

Ejemplares similares